| Literature DB >> 21414223 |
Einar Hopp1, Ketil Lunde, Svein Solheim, Svend Aakhus, Harald Arnesen, Kolbjørn Forfang, Thor Edvardsen, Hans-Jørgen Smith.
Abstract
BACKGROUND: Trials have brought diverse results of bone marrow stem cell treatment in necrotic myocardium. This substudy from the Autologous Stem Cell Transplantation in Acute Myocardial Infarction trial (ASTAMI) explored global and regional myocardial function after intracoronary injection of autologous mononuclear bone marrow cells (mBMC) in acute anterior wall myocardial infarction treated with percutaneous coronary intervention.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21414223 PMCID: PMC3068099 DOI: 10.1186/1532-429X-13-22
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Figure 1Baseline apical tagging analysis in a 49 year old male patient in the mBMC group. Upper part: The curves represent strain in the apical segments, analyzed with HARP software from a short axis CMR tagging sequence. The vertical box represents the end systolic frame (F6). There is almost normal function in the lateral wall, dysfunction in the inferior wall, while septum and the anterior wall are almost akinetic with possible post-systolic contraction. Note increasing noise during diastolic frames, due to T1 relaxation of the tagged myocardium. Lower part: Left: Short axis apical LGE image with hyperintensity in the anterior wall, septum and part of the inferior wall. Mid and right: Short axis apical end diastolic (mid) and end systolic (right) tagging images with application of the semi-automatically traced lines from HARP software. Circumferential mid-wall end systolic strain was calculated from deformation of the orange mid-wall line.
Patient characteristics at admission
| mBMC (n = 15) | Controls (n = 13) | p-value | |
|---|---|---|---|
| Age - years | 58.5 ± 8.9 | 58.7 ± 9.7 | 0.965 |
| Female sex - no | 3 | 3 | 0.843 |
| Body mass index | 25.7 ± 2.6 | 27.1 ± 3.2 | 0.240 |
| Current smokers - no | 5 | 3 | 0.836 |
| Hypertension - no | 2 | 3 | 0.502 |
| Diabetes mellitus - no | 1 | 1 | 0.916 |
| Previous angina - no | 2 | 4 | 0.262 |
| Blood pressure - mm Hg | |||
| systolic | 133 ± 21 | 125 ± 18 | 0.320 |
| diastolic | 79 ± 12 | 78 ± 13 | 0.807 |
| Heart rate - beats/min | 71 ± 12 | 80 ± 14 | 0.090 |
| Time from symptom onset to PCI - min | 239 ± 100 | 228 ± 112 | 0.780 |
| Maximum creatine kinase MB - μg/l | 382 ± 130 | 334 ± 143 | 0.376 |
Global and regional results; all patients (n = 28)
| Baseline | 6 months | ||||||
|---|---|---|---|---|---|---|---|
| mBMC | controls | p-value 1 | mBMC | controls | p-value 2 | ||
| EDV - ml | 175.1 ± 48.7 | 176.8 ± 52.8 | 0.932 | 174.9 ± 60.0 | 174.3 ± 62.3 | 0.828 | |
| ESV - ml | 91.2 ± 35.2 | 84.9 ± 41.0 | 0.668 | 87.6 ± 44.9 | 78.0 ± 42.3 | 0.674 | |
| EF - % | 49.3 ± 9.5 | 54.1 ± 11.3 | 0.233 | 52.4 ± 11.9 | 57.9 ± 10.1 | 0.610 | |
| LV mass - g | 168.6 ± 28.3 | 171.5 ± 42.1 | 0.831 | 162.4 ± 30.8 | 160.4 ± 41.1* | 0.379 | |
| infarct mass - g | 38.6 ± 23.3 | 45.7 ± 29.5 | 0.484 | 37.6 ± 20.5 | 35.7 ± 20.4* | 0.034 | |
| infarct percent - % | 22.1 ± 12.4 | 26.4 ± 14.8 | 0.410 | 22.2 ± 10.8 | 22.0 ± 11.0* | 0.026 | |
| global strain - % | -11.1 ± 2.4 | -11.9 ± 3.4 | 0.512 | -11.1 ± 2.6 | -13.1 ± 2.4* | 0.027 | |
| twist - ° | 11.3 ± 3.6 | 12.8 ± 5.4 | 0.365 | 12.6 ± 4.3 | 11.8 ± 3.7 | 0.411 | |
| mass - g | 103.0 ± 39.6 | 103.9 ± 37.6 | 0.955 | 100.3 ± 39.9 | 96.2 ± 34.5* | 0.217 | |
| infarct mass - g | 38.6 ± 23.3 | 45.7 ± 29.5 | 0.484 | 37.6 ± 20.5 | 35.7 ± 20.4* | 0.034 | |
| infarct percent - % | 34.4 ± 13.6 | 41.5 ± 17.7 | 0.242 | 34.3 ± 12.6 | 35.0 ± 11.6* | 0.084 | |
| strain - % | -9.7 ± 3.4 | -9.3 ± 4.1 | 0.770 | -10.2 ± 3.3 | -11.8 ± 3.0* | 0.009 | |
| mass - g | 32.3 ± 22.6 | 35.0 ± 26.2 | 0.855 | 33.7 ± 21.4 | 33.6 ± 24.0 | 0.519 | |
| infarct mass - g | 29.0 ± 23.0 | 32.5 ± 25.2 | 0.804 | 26.6 ± 17.7 | 26.1 ± 19.5 | 0.468 | |
| infarct percent - % | 86.8 ± 7.4 | 90.3 ± 6.1 | 0.377 | 77.6 ± 4.3* | 76.6 ± 11.4* | 0.401 | |
| strain - % | -2.0 ± 1.5 | -6.6 ± 5.6 | 0.107 | -2.4 ± 1.4 | -8.6 ± 4.9 | 0.108 | |
| mass - g | 64.4 ± 22.1 | 66.5 ± 24.3 | 0.816 | 61.1 ± 22.8 | 63.2 ± 24.0 | 0.965 | |
| strain - % | -14.4 ± 2.4 | -14.9 ± 2.3 | 0.560 | -14.3 ± 3.3 | -15.6 ± 2.3 | 0.195 | |
p-value 1 refers to between group differences at baseline (two sample t-test). p-value 2 refers to between group differences in changes from baseline (analysis of covariance). *p < 0.05 for intra-group changes from baseline, evaluated by paired sample t-test.
Selected results; patients with baseline EF < median (51.9%)
| Baseline | 6 months | ||||||
|---|---|---|---|---|---|---|---|
| mBMC | controls | p-value 1 | mBMC | controls | p-value 2 | ||
| EDV - ml | 183.2 ± 46.1 | 202.9 ± 49.3 | 0.641 | 194.6 ± 64.4 | 191.6 ± 55.6 | 0.162 | |
| ESV - ml | 105.1 ± 33.1 | 114.8 ± 38.1 | 0.640 | 107.7 ± 43.4 | 95.2 ± 43.6* | 0.028 | |
| EF - % | 43.3 ± 6.4 | 43.7 ± 7.2 | 0.947 | 45.8 ± 7.1 | 51.9 ± 8.8* | 0.386 | |
| infarct percent - % | 28.8 ± 10.7 | 33.5 ± 12.1 | 0.505 | 27.2 ± 8.8 | 28.7 ± 12.1* | 0.071 | |
| global strain - % | -10.0 ± 2.4 | -11.3 ± 2.9 | 0.536 | -11.4 ± 2.8 | -13.0 ± 2.8 | 0.189 | |
| infarct percent - % | 41.0 ± 12.4 | 46.6 ± 11.9 | 0.463 | 37.9 ± 10.1* | 38.8 ± 11.4* | 0.053 | |
| strain - % | -8.7 ± 2.9 | -8.9 ± 2.7 | 0.738 | -9.9 ± 3.1 | -11.7 ± 2.4* | 0.205 | |
| infarct percent - % | 86.8 ± 7.4 | 90.5 ± 7.7 | 0.462 | 77.6 ± 4.3* | 79.2 ± 12.7 | 0.327 | |
| strain - % | -2.0 ± 1.5 | -4.6 ± 4.9 | 0.221 | -2.4 ± 1.4 | -8.6 ± 5.9 | 0.027 | |
p-value 1 refers to between group differences at baseline (Mann-Whitney). p-value 2 refers to between group differences in changes from baseline (Mann-Whitney). *p < 0.05 for intra-group differences from baseline, evaluated by Wilcoxon signed rank test.
Figure 2Bull's eye plots over baseline LGE and strain in the 16 LV segments model. 2 a: Average infarct involvement (percent) in each segment (n = 448). 2 b: Average strain (percent) in each segment (n = 402). Negative strain values indicate myocardial shortening, and a strain value with amplitude higher than -14% is considered normal.
Correlation between strain development and infarct mass in controls
| Beta (standardized) | R | p-value | |
|---|---|---|---|
| LV infarct mass at baseline | -0.663 | 0.663 | 0.019 |
| Change of infarct mass | 0.665 | 0.665 | 0.018 |
| Dependent variable: change of LV strain | |||
Linear regression analysis for correlation between change of LV strain (dependent) and baseline LV infarct mass and change of LV infarct mass in controls (n = 12).